US FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks list
Context
The FDA's proposal to exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B bulks list could impact the competitive landscape for these drugs in the compounding pharmacy market. This decision might lead to heightened scrutiny on these products and affect their availability or pricing dynamics, which could, in turn, influence the stock performance of Eli Lilly and Novo Nordisk in both the short and medium term.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#NOVO NORDISK A/S#NOVOB.DC#FDA#IMPORTANT#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#GLOBAL EQUITIES